Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03967223 |
| Title | Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO) |
| Acronym | IGNYTE-ESO |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | Adaptimmune |
| Indications | |
| Therapies | |
| Age Groups: | senior | child | adult |
| Covered Countries | USA | NLD | ITA | GBR | FRA | ESP | CAN |